Dr. Elisabeth Daguenet|Cancer research|Best Researcher Award

Dr. Elisabeth Daguenet | Cancer research|Best Researcher Award

Dr. Elisabeth Daguenet at CHU de Saint-Etienne,France

PROFILE  

scopus

 

Early Academic Pursuits 🎓

The journey into chronic myeloid leukemia (CML) research for many esteemed researchers began with a strong foundation in biomedical sciences, often pursued at prominent universities worldwide. Individuals drawn to this field typically engage in intensive studies in molecular biology, genetics, and oncology. By acquiring a strong academic base, they develop a passion for understanding cancer biology and molecular pathways, which ultimately leads to a specialization in CML, a type of blood cancer that has evolved significantly in terms of treatment and patient prognosis.

Early on, these researchers often excel in various scientific competitions, securing scholarships or internships, which provide invaluable laboratory experience. Many join research teams focusing on leukemia, gaining insights into molecular dynamics, cellular responses, and how early molecular response (EMR) can predict deeper responses in CML patients.

Professional Endeavors in Chronic Myeloid Leukemia 🧬

As they advance in their careers, these scientists and oncologists become affiliated with medical institutions, research hospitals, and pharmaceutical companies dedicated to advancing leukemia treatment. Their work emphasizes real-world data collection, the accuracy of clinical trials, and translating laboratory findings into practical treatment solutions for CML patients.

In professional settings, they may lead trials to evaluate tyrosine kinase inhibitors (TKIs)—a cornerstone treatment for CML—and examine patients’ responses to these drugs. These trials often reveal trends, such as the role of the initial molecular response in predicting a deep molecular response, which can influence treatment protocols. However, these studies also underscore that EMR alone may not guarantee treatment-free remission (TFR) maintenance, particularly in real-world settings. Through these roles, they often mentor young scientists and clinicians, fostering a new generation of leukemia researchers.

Contributions and Research Focus 🧫

The contributions of researchers in this field are substantial, especially in the exploration of CML treatment responses. Their research often focuses on identifying biomarkers that predict EMR, deep molecular response (DMR), and the viability of treatment-free remission (TFR). This research is crucial as it helps clinicians understand which patients are more likely to maintain remission after stopping treatment, potentially enhancing their quality of life by reducing dependency on medications.

Their work also explores the impact of various TKIs on the molecular response, aiming to discover why some patients maintain remission without treatment while others do not. The analysis of “real-world” cohorts—patients outside of clinical trial settings—adds a vital dimension to this research, providing a more practical perspective on how different factors impact TFR. Additionally, these studies often examine the psychological and social aspects of remission in leukemia patients, ensuring a holistic approach to cancer care.

Accolades and Recognition 🏅

Researchers who make strides in understanding CML are often recognized by prestigious oncology and hematology organizations worldwide. They may receive awards such as “Young Investigator Awards” or “Lifetime Achievement” distinctions from organizations like the European Hematology Association (EHA), American Society of Hematology (ASH), or similar bodies. These awards celebrate their commitment to advancing leukemia treatment and improving patient outcomes.

Publications in high-impact journals, invitations to speak at global conferences, and editorial roles in scientific publications also bring recognition. Through these platforms, they share their findings with a wider audience, spreading knowledge that shapes the future of CML treatment.

Impact and Influence 🌟

The impact of this work extends far beyond individual patient outcomes, transforming the landscape of CML treatment globally. Researchers studying the initial molecular response in CML patients play a significant role in refining the approach to personalized medicine. By highlighting the nuances of TFR maintenance, they guide oncologists in creating treatment plans tailored to each patient’s molecular profile, fostering a more effective and patient-centered treatment protocol.

Furthermore, this research influences medical guidelines, ensuring that healthcare providers have the most current information on EMR and DMR in real-world settings. This influence translates into better decision-making for oncologists worldwide, who can offer more accurate prognoses and support to CML patients.

Legacy and Future Contributions 🌱

The legacy of these researchers is one of resilience, innovation, and dedication to improving lives. Their work has fundamentally shifted the understanding of CML and has inspired a focus on achieving TFR, a dream outcome for many cancer patients. By shedding light on the predictors of TFR and the limitations of relying solely on EMR for treatment decisions, they encourage ongoing research that pushes the boundaries of cancer treatment.

In the future, the work may inspire genetic and pharmacological advancements, enabling scientists to uncover new biomarkers or develop novel TKIs with fewer side effects. Their research also lays a foundation for upcoming generations of cancer researchers, fostering a continuous cycle of inquiry, discovery, and refinement in leukemia treatment.

Conclusion 📝

In summary, the pursuit of understanding the molecular response in CML patients represents an extraordinary commitment to scientific advancement and patient care. These researchers build a legacy that impacts lives on a personal and global scale, contributing to the evolution of oncology and the prospect of a world where CML remission and ultimately cure become a widespread reality. Through their efforts, CML patients around the world can hope for not only better treatments but a pathway toward sustained remission and a life free from cancer treatment.

🎓Publication 

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

  • Authors   :Saugues, S., Lambert, C., Daguenet, E., Pereira, B., Berger, M.G.
  • Journal    : Haematologica
  • Year         :2024

Baseline DSB repair prediction of chronic rare Grade ≥ 3 toxicities induced by radiotherapy using classification algorithms

  • Authors   : Muggiolu, G., Sauvaigo, S., Libert, S., Deutsch, E., Magné, N.
  • Journal    : Radiation Research
  • Year         :2024

Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study

  • Authors   :Garderet, L., Ouldjeriouat, H., Bekadja, M.-A., Lambert, J., Cornillon, J.
  • Journal    : British Journal of Haematology
  • Year         :2024

Differential Formation of Stress Granules in Radiosensitive and Radioresistant Head and Neck Squamous Cell Carcinoma Cells

  • Authors   : Louati, S., Wozny, A.-S., Malesys, C., Magné, N., Rodriguez-Lafrasse, C.
  • Journal    :International Journal of Radiation Oncology Biology Physics
  • Year         :2024

Correction to: ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party (Bone Marrow Transplantation

  • Authors   :Penack, O., Peczynski, C., Boreland, W., Moiseev, I., Peric, Z.
  • Journal    :Bone Marrow Transplantation
  • Year         :2024

 

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy at HMC, QU, WHO,Qatar

PROFILE  

orcid

Google scholar

Early Academic Pursuits 🎓

The foundation of this individual’s career is rooted in a strong academic background. Although specific details about early education are not mentioned, the advanced roles undertaken in both pharmaceutical and medical sectors suggest a deep understanding and expertise in pharmacology, clinical pharmacy, and sterile medication preparation. Their professional journey likely began with formal education in pharmacy, complemented by continuous professional development and specialized training. The fact that they were entrusted with high-responsibility roles, such as acting pharmacy director, regulatory manager, and clinical instructor, indicates a robust educational foundation coupled with a commitment to lifelong learning.

Their association with the SAAD Training Institute, affiliated with Duke University, is an important academic highlight. This affiliation points to their exposure to global standards in pharmaceutical education and practices, which undoubtedly shaped their approach to teaching and developing competencies within their professional network.

Professional Endeavors 🏥

SAAD Specialist Hospital, Saudi Arabia (Dec 2003 – Jun 2006)
This phase of the career showcases the breadth and depth of their professional experience in Saudi Arabia’s healthcare system, particularly within SAAD Specialist Hospital, a prominent medical institution. Initially starting as a Pediatric Clinical Pharmacist in 2003, they quickly rose through the ranks to take on more senior and specialized roles.

  • Education and Development Coordinator (Dec 2005 – Jun 2006): In this role, they focused on the educational advancement of the hospital’s healthcare professionals. This position required overseeing staff training and ensuring adherence to the latest pharmaceutical guidelines and practices, fostering an environment of continual learning and improvement.
  • Aseptic Technology Instructor, SAAD Training Institute (Jun 2004 – Jun 2006): As an instructor, they were responsible for training both pharmacists and non-pharmacists in aseptic techniques, particularly in the preparation of sterile medications. The affiliation with Duke University highlights the high standard of education and training delivered.
  • IV Room Supervisor (Jun 2004 – Jun 2006): Managing the IV Room, they oversaw sterile medication preparation for neonates, pediatric, and adult patients, dealing with complex formulations such as Total Parenteral Nutrition (TPN), chemotherapy drugs, and desensitization protocols.

These roles reflect a strong command over clinical pharmacy, sterile practices, and pharmaceutical education, making them a critical contributor to healthcare improvement in Saudi Arabia.

Governmental Hospital of Tropical Diseases, Ministry of Health, Egypt (Dec 1997 – Dec 2003)
Their role at this governmental hospital in Egypt demonstrates significant leadership and management skills within the pharmaceutical services sector.

  • Inpatient Pharmacist (Dec 1997 – Sep 2002): During this period, they were entrusted with the pharmaceutical care of inpatient services, managing medication therapy and ensuring safe medication administration.
  • Acting Pharmacy Director (Oct 2002 – Dec 2003): As Acting Pharmacy Director, they assumed full authority over the hospital’s pharmacy operations. This role required balancing clinical duties with administrative responsibilities, overseeing drug inventories, ensuring compliance with pharmaceutical regulations, and leading the pharmacy staff.

This progression in Egypt’s healthcare sector speaks to their competence, leadership abilities, and the trust placed in them to manage essential healthcare operations.

CBIC Medical, Pharmaceutical Development, and Consultation Company (Nov 2002 – Dec 2003)
In parallel with their role in Egypt’s healthcare system, they also held a position in CBIC Medical, which involved regulatory and marketing responsibilities in the pharmaceutical sector.

  • Regulatory and Marketing Manager: They were tasked with navigating complex pharmaceutical regulations while overseeing the marketing of medical products. This role required a deep understanding of both the regulatory landscape and market dynamics.
  • Clinical and Marketing Instructor: Leveraging their extensive pharmaceutical knowledge, they conducted training programs for medical representatives, teaching them about new products and re-launched products, as well as imparting advanced marketing strategies.

This role illustrates their ability to work across both clinical and commercial spheres, bridging the gap between product development, regulatory compliance, and market outreach.

Contributions and Research Focus 🔬

While explicit research endeavors are not mentioned, their extensive work in teaching, sterile medication preparation, and regulatory roles highlights a career deeply rooted in evidence-based practices. Their focus on educating healthcare professionals in critical areas like aseptic techniques and sterile medication preparation indicates a dedication to improving healthcare outcomes through rigorous training.

The supervisory roles in sterile medication preparation, particularly for vulnerable populations such as neonates and pediatric patients, point to a keen interest in precision pharmacy and patient safety, areas likely to have been influenced by research in clinical pharmacology.

Accolades and Recognition 🏅

The trust and leadership roles assigned to them—ranging from being an Acting Pharmacy Director to a supervisor and instructor at the SAAD Specialist Hospital—reflect the high regard in which they were held by their peers and employers. Their instructional role at the SAAD Training Institute, affiliated with Duke University, is a significant marker of their expertise and the recognition they received in the field of pharmaceutical education.

Impact and Influence 🌍

Their influence spans multiple facets of healthcare, particularly in the realms of education, clinical pharmacy, and sterile medication practices. Through teaching roles, both at SAAD and CBIC Medical, they shaped the competencies of numerous healthcare professionals, directly impacting patient safety and care quality.

As a supervisor in the preparation of sterile medications, they ensured that some of the most vulnerable patients—neonates and those undergoing chemotherapy—received safe, effective treatments. This role would have had a profound impact on patient outcomes, underscoring their influence in clinical settings.

Legacy and Future Contributions 📜

Their legacy is marked by the high standards of training and education they provided, particularly in aseptic techniques and sterile medication preparation. The knowledge they imparted to medical representatives and pharmacy staff will continue to influence healthcare practices long after their direct involvement.

🎓Publication 

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced …

  • Authors   :Jeffrey S Weber, Reinhard Dummer, Veerle de Pril, Celeste Lebbé, F Stephen Hodi, MDX010‐20 Investigators
  • Journal    : Cancer
  • Year         :2013

An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital

  • Authors   :Eva Rämme Bremberg, Christina Hising, Urban Nylén, Hans Ehrsson, Staffan Eksborg
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2006

The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy

  • Authors   : Ahmet S Boşnak, Nevzat Birand, Ömer Diker, Abdikarim Abdi, Bilgen Başgut
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2019

Denosumab in hypercalcemia of malignancy: a case series

  • Authors   : Amanda Dietzek, Kelly Connelly, Michael Cotugno, Sylvia Bartel, Anne M McDonnell
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2015

Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis

  • Authors   :Sha Li, Tsz-him So, Guoyi Tang, Hor-Yue Tan, Ning Wang, Bacon Fung Leung Ng, Chris Kam Wa Chan, Edwin Chau-Leung Yu, Yibin Feng
  • Journal    :Frontiers in Oncology
  • Year         :2020